Viewing Study NCT06610097



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06610097
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-09-13

Brief Title: TNBC Gut Microbiota During Neoadjuvant Treatment
Sponsor: None
Organization: None

Study Overview

Official Title: Impacts of Diet Activity and Mood on a Dynamic Gut Microbiota During Treatment for Triple-negative Breast Cancer
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The gut microbiome is made up of the microbes such as bacteria viruses and other organisms too small to see with the naked eye that live in the digestive tract and has been shown to be important in metabolizing food extracting vitamins and nutrients from food and maintaining a healthy gut lining The gut microbiome plays an important role in overall health and has been shown to dynamically change in response to early-stage triple-negative breast cancer-directed therapies which in turn has been associated with worse outcomes As the gut microbiome can be further modulated with dietary changes during cancer treatment it is an ideal potential modifiable risk factor in cancer patients However due to multiple confounding factors such as dietary intake mood and activity its utility as part of the oncologic clinical assessment remains unclear

In this prospective randomized controlled study the investigators propose to recruit up to 30 early-stage TNBC patients to randomize to a personalized nutritional intervention of a high-fiber diet coached by a registered dietician versus educational handout alone during neoadjuvant treatment The investigators propose to study the gut microbiota through stool sample analysis among early-stage triple-negative breast cancer patients undergoing neoadjuvant ie before surgery chemotherapy - immunotherapy The investigators will also study how the gut microbiota can be further modulated with a high-fiber diet and the investigators hypothesize that a high-fiber diet may play a protective role in preserving gut microbial diversity As part of the nutritional intervention the investigators propose to administer nutritional counseling with a registered dietitian RD to increase fiber intake and tracking performance status activity and mood during neoadjuvant treatment Finally the investigators propose to survey participants after study completion through one-on-one interviews to determine whether participants experienced improved overall patient satisfaction in supportive care during their treatment
Detailed Description: This is a randomized prospective study with a small group of 30 patients pilot study Once participants are enrolled they will be randomized in a 21 ratio of either the nutritional intervention personalized counseling on increasing fiber intake and maintaining adequate caloric intake during breast cancer treatment or an educational handout on increasing fiber intake Randomization will be concealed using a random number generator Investigators and healthcare providers will not be blinded due to the nature of the intervention itself but all documentation related to the personalized nutritional intervention will not be part of the participants electronic medical record Co-investigators completing the data analysis will be blinded to participants group assignments

Consent will be obtained upon enrollment Variables to be collected as part of the baseline demographics questionnaire include age gender marital status education level employment status annual income residence ZIP code BMI medications and dose TNBC stage at diagnosis and treatment types

Participants will complete interim medication updates including antibiotic use Interim Survey gastrointestinal symptoms using the PROMIS GI symptom assessment dietary intake NCI-DSQ with two 24-hour food logs performance status FACT-G Scale anxiety GAD-7 and depression PHQ-9 and physical activity RAPA If participants report moderate-severe anxiety andor depression through the GAD-7 andor PHQ-9 surveys respectively they will be notified by telephone or email to contact their primary care provider or oncologist to seek prompt evaluation Stool samples will be collected at baseline pre-treatment 6-week 12-week 18-week and 24-week timepoints The 6-week interval period was selected based on expected treatment cycles with dose-dense doxorubicincyclophosphamide and Taxol - pembrolizumab This interval was also selected based on the minimum amount of time expected for potential changes in dietary intake and symptoms during treatment Survey reminders will be sent via the app every 6 weeks and data will be exported to RedCap

The nutritional intervention for the treatment group -- personalized counseling on increasing fiber intake and maintaining adequate caloric intake during treatment -- will be administered as 1 a 60-minute initial telehealth consultation within the first week of study enrollment and 2 up to two 30-minute follow-ups throughout the study ideally the first follow-up within 6 weeks of study enrollment These sessions will be led by a registered dietitian using cultural awareness and symptom assessment Session notes will be included in the participants medical records Control participants intervention will be an educational handout on increasing fiber intake San Diego State University SDSU masters students in Exercise and Nutritional Science will assist all participants with completing two 24-hour ASA24 food logs at each timepoint along with other surveys Nutritional composition reported in 24-hour logs will be analyzed at SDSU using ASA24

Participants will collect stool samples using the Zymo Research kit which has previously been shown to be equally efficacious as a larger stool sample scoop10 mailed to their home This kit includes a Fecal Collection Tube a Feces Catcher a Biohazard Bag Gloves and multi-language instructions To encourage participation and retention participants will be given a 40 gift certificate per stool sample with up to 200 total compensation Participants will mail stool samples to the Scripps Biorepository and processed for storage at -80 degrees C Once all samples are collected they will be sent to the Scripps Genomics Core for DNA extraction and 16S sequencing Sequencing data analysis by the CCBB will include taxonomic classification abundance tables diversity analysis alpha and beta indices and principal component analysis PCA plots Subset analyses will compare participants with highlow fiber consumption highlow caloric intake overweightnot overweight by BMI and cancer-directed treatment chemotherapy alone or with immunotherapy

Survey data will be imported into GraphPad Prism for visualization and analyses For each survey item collected at all 5 time points a mixed effects model will be used where the survey item result is the dependent variable group control or nutritional intervention and time point are fixed effects and participant is treated as a random effect The mixed effects model uses restricted maximum likelihood estimation to account for missing values Residuals will be examined to ensure approximation of normality is met P-values will be reported for each fixed effect group and time and the interaction between these effects reported as time x group

For TME analysis up to 3 participants with high-fiber dietary intake who experience pCR and 3 participants with residual disease ie up to 6 total will be selected based on retrospective chart review and biopsy samples pre- and post-treatment will be identified through the Department of Pathology Samples will be further processed and mounted onto slides each with 1 participant with matched pre- and post-neoadjuvant treatment samples per slide for GeoMx spatial transcriptional profiling of 96 regions of interest ROIs through the Scripps Genomics Core The CCBB will perform statistical analysis to identify signaling pathways and immune cell composition in TNBC

At the end of the study participants will be offered participation in a one-on-one session via video conferencing platform such as Zoom to provide an opportunity for participants to share in their own words their experiences in the study and in using the survey app Specifically participants will be asked to discuss the utility of educational materials provided ease of navigating the study app and participating in the study and other feedback that will help medical oncologists and dietitians continuously improve patients experience during neoadjuvant treatment Participants who uninstall the CareEvolution app or have not engaged with the app for over 60 days will be disenrolled from the study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None